# BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

> **NCT00931801** · PHASE4 · COMPLETED · sponsor: **Community Research Initiative of New England** · enrollment: 43 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** atazanavir/raltegravir
- **DRUG:** atazanavir/raltegravir
- **DRUG:** atazanavir/tenofovir/emtricitabine

## Key facts

- **NCT ID:** NCT00931801
- **Lead sponsor:** Community Research Initiative of New England
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-02
- **Final completion:** 2012-03
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2017-07-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00931801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00931801, "BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00931801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*